Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine

1998 ◽  
Vol 128 (2) ◽  
pp. 183-188 ◽  
Author(s):  
K Narasimha Rao ◽  
R.K Bhattacharya ◽  
S.R Venkatachalam
Keyword(s):  
Thymidylate Synthase ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Chronic Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Phenanthroindolizidine Alkaloids

scholarly journals Erythroid Homograft Following Leukocyte Transfusion in a Patient with Acute Leukemia

Blood ◽  
1965 ◽  
Vol 26 (5) ◽  
pp. 587-596 ◽  
Author(s):  
ROBERT H. LEVIN ◽  
JACQUELINE WHANG ◽  
PAUL P. CARBONE ◽  
EMIL J. FREIREICH
Keyword(s):  
Bone Marrow ◽  
Acute Leukemia ◽  
Blood Group ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Chronic Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Factors Influencing ◽  
Female Donor ◽  
Treatment Of Infection

Abstract A patient with acute lymphocytic leukemia developed a functioning erythroid homograft after transfusion of leukocytes from donors with chronic myelocytic leukemia. Two donor populations were observed cytogenetically, by examination of the recipient’s marrow for sex and Philadelphia chromosomes. The cells from a female donor of different blood group eventually repopulated the entire bone marrow and were exclusively responsible for the function of the homograft. Although the donor was anemic and required periodic transfusions, her transplanted cells caused normal erythropoiesis in the recipient for a prolonged period. During this time the recipient enjoyed remission of acute leukemia but expired as a result of overwhelming infection. It is proposed that multiple transfusions of leukocytes is a useful technic for treatment of infection, for increasing knowledge of factors influencing hematopoiesis, and for studying approaches to effective immunotherapy of leukemia.

scholarly journals Gambaran Laboratorium Leukemia Kronik di Bagian Penyakit Dalam RSUP Dr. M. Djamil Padang

2013 ◽  
Vol 2 (3) ◽  
pp. 141
Author(s):  
Muthia Rendra ◽  
Rismawati Yaswir ◽  
Akmal M Hanif
Keyword(s):  
Internal Medicine ◽  
Peripheral Blood ◽  
Blood Cells ◽  
Lymphocytic Leukemia ◽  
Chronic Myelocytic Leukemia ◽  
Laboratory Findings ◽  
Medicine Department ◽  
Chronic Leukemia ◽  
Myelocytic Leukemia ◽  
Moderate Anemia

AbstrakLeukemia merupakan penyakit keganasan sel darah yang berasal dari sumsum tulang ditandai oleh proliferasi sel-sel darah putih, dengan manifestasi adanya sel-sel abnormal dalam darah tepi. Pada tahun 2006, leukemia berada pada urutan ke-5 dari keseluruhan penderita kanker di Indonesia. Leukemia kronik merupakan leukemia yang paling sering terjadi pada dewasa dan lanjut usia. Secara umum leukemia kronik diklasifikasikan atas Leukemia Granulositik Kronik (LGK) dan Leukemia Limfositik Kronik (LLK). Leukemia kronik yang perjalanannya lambat dan diiringi oleh gejala yang tidak khas, maka penelitian ini bertujuan untuk mengetahui gambaran laboratorium leukemia kronik di bagian Peyakit Dalam RSUP DR. M. Djamil Padang. Jenis penelitian ini adalah deskriptif retrospektif. Instrumen yang digunakan pada penelitian ini adalah data sekunder yang diperoleh dari Instalasi Rekam Medik RSUP Dr. M. Djamil Padang berupa data pasien leukemia kronik yang dirawat di Bagian Penyakit Dalam RSUP Dr. M. Djamil Padang sejak 1 Januari 2010 – 31 Desember 2012. Hasil penelitian ini menunjukkan bahwa dari 16 kasus leukemia granulositik kronik terdapat 37,5% pasien mengalami anemia sedang, 100% leukositosis, jumlah trombosit dapat menurun, normal, dan meningkat dengan presentase masing-masing 25%, 25%, dan 50%. Gambaran eritrosit sebagian besar normositik anisositosis. Separuh pemeriksaan darah tepi menunjukkan peningkatan persentasi mielosit, 31,25% menunjukkan peningkatan persentasi metamielosit dan eosinofil, serta sebagian besar menunjukkan presentasi blast. Sedangkan gambaran sumsum tulang hiperseluler, penekanan eritropoetik, mielopoetik hiperaktif, dan trombopoetik dalam batas normal. Leukemia limfositik kronik yang terdiri dari 1 kasus menunjukkan gambaran laboratorium berupa anemia sedang, leukositosis, trombositopenia, gambaran eritrosit nomokrom anisositosis, peningkatan jumlah leukosit, peningkatan jumlah limfosit, presentasi smudge cell, dan ditemukan presentasi blast pada darah tepi, tetapi selularitas tidak dapat dinilai.Kata kunci: leukemia kronik, darah tepi, BMPAbstractLeukemia is a malignant disease of blood cells derived from the bone marrow characterized by the proliferation of white blood cells, with the manifestation of the abnormal cells in the peripheral blood. In 2006, leukemia was ranked 5th of all cancer patients in Indonesia. Chronic leukemia is the most common leukemia in adult and the elderly. In general, chronic leukemia classified on chronic myelocytic leukemia (CML) and chronic lymphocytic leukemia (CLL). The onset of chronic leukemia is insidious and accompanied by symptoms that are not typical, this research aims to describe the laboratory findings of chronic leukemia patients treated at Internal Medicine Department of Dr. M. Djamil Hospital Padang.This research is a retrospective descriptive research. The instruments used in this research are the secondary data derived from the Medical Record Departement Dr. M. Djamil Hospital Padang in the form of leukemia chronic patients’ data who were treated in Internal Medicine Department of Dr. M. Djamil Hospital Padang since January 1st 2010 – December 31st 2012. The results of this research showed that of 16 cases of chronic myelocytic leukemia contained 37.5% of the patients had moderate anemia, leukocytosis 100%, platelet count can be decreased, normal, and increased the percentage of each 25%, 25%, and 50%. The morphology of erythrocytes mostly normocytic anisocytosis. Half of peripheral blood examination showed an increase in the percentage of myelocyte, 31.25% showed an increase in the percentage metamyelocyte and eosinophils, as well as most of the shows presentation blast. The bone marrow are hypercellular, compressing erythropoietic, myelopoietic hyperactivity and thrombopoietic mostly normal in number. Chronic lymphocytic leukemia consisting of 1 case shows the laboratory findings are moderate anemia, leukocytosis, thrombocytopenia, the morphology of erythrocyte is normochromic anisocytosis, leukocytes increase in number, increase in the number of lymphocytes, presentations smudge cells, and blast presentation is found in the peripheral blood, but the cellularity not be assessed.Keywords: chronic leukemia, peripheral blood, BMP

scholarly journals The Granulocyte Response to Endotoxin in Patients with Hematologic Disorders

Blood ◽  
1964 ◽  
Vol 23 (5) ◽  
pp. 581-599 ◽  
Author(s):  
JOHN C. MARSH ◽  
SEYMOUR PERRY
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Bacterial Endotoxin ◽  
Chronic Myelocytic Leukemia ◽  
Hematologic Disorders ◽  
Recent Onset ◽  
Myelocytic Leukemia ◽  
Normal Individuals

Abstract Sixty patients with disorders involving the bone marrow were tested with a purified bacterial endotoxin given intravenously. Their leukocyte and granulocyte responses were evaluated based on criteria established in normal individuals and in patients with leukocytosis. Results in patients with chronic myelocytic leukemia, untreated or in relapse, suggest that adequate granulocyte mobilization may still occur if the disease has been of recent onset or if the count has recently started to rise in spite of therapy. Patients in remission demonstrated adequate granulocyte reserves. Most patients with chronic lymphocytic leukemia in this study responded well with an increase in the number of granulocytes. Patients with multiple myeloma as a group showed inadequate granulocyte mobilization. This study demonstrates that endotoxin testing is useful for the evaluation of bone marrow granulocyte reserves in patients with hematologic disorders.

scholarly journals Plasma Lactic Dehydrogenase and Phosphohexose Isomerase in Leukemia

Blood ◽  
1958 ◽  
Vol 13 (3) ◽  
pp. 245-257 ◽  
Author(s):  
M. C. BLANCHAER ◽  
P. T. GREEN ◽  
J. P. MACLEAN ◽  
M. J. HOLLENBERG
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Cell Count ◽  
White Cell Count ◽  
Lactic Dehydrogenase ◽  
High Plasma ◽  
Lymphocytic Leukemia ◽  
Chronic Myelocytic Leukemia ◽  
Phosphohexose Isomerase ◽  
Myelocytic Leukemia ◽  
Plasma Enzymes

Abstract Two enzymes, lactic dehydrogenase (LD) and phosphohexose isomerase (PHI), were measured in the plasma of 30 patients with leukemia and compared with the findings in 66 control subjects. Abnormally elevated PHI levels were found in both acute and chronic myelocytic leukemia, but not in lymphocytic leukemia. The plasma LD was increased above normal in acute and chronic myelocytic leukemia, in acute lymphocytic, but not in chronic lymphocytic leukemia. Both enzymes were normal or only slightly raised in three patients with the aleukemic type of the disease. Hemolytic anemia in seven leukemic patients was associated with high plasma LD values in the presence of relatively low PHI levels. Results of serial enzyme studies from the time of diagnosis until death indicated that both plasma enzymes, but especially the LD, usually reflected changes in the course of the disease-falling during remissions and rising during relapses. In most cases this enzyme paralleled the leukocyte level but occasionally indicated the onset of a relapse or remission before the white cell count had begun to change.

scholarly journals A Comparative Study of Two Regimens of Combination Chemotherapy in Acute Leukemia

Blood ◽  
1958 ◽  
Vol 13 (12) ◽  
pp. 1126-1148 ◽  
Author(s):  
EMIL FREI ◽  
JAMES F. HOLLAND ◽  
MARVIN A. SCHNEIDERMAN ◽  
DONALD PINKEL ◽  
GEORGE SELKIRK ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Survival Time ◽  
Median Survival ◽  
Combination Chemotherapy ◽  
Drug Toxicity ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Remission Status

Abstract A comparative clinical trial of two regimens of combination chemotherapy has been accomplished in acute leukemia by four separate medical and pediatric services. Sixty-five patients were allocated at random to one of two treatment programs. Daily administration of methotrexate with daily 6-mercaptopurine has been compared to methotrexate every third day in the same total dose with daily 6-mercaptopurine. No difference in frequency of remission, extent of remission or toxicity was observed between the two groups. Among those patients who attained remission status, however, duration of remission (P = .05-.10) and of survival (P = <.05) was longer for the continuous group. All remissions in children occurred in acute lymphocytic leukemia, whereas all remission in adults were observed in acute myelocytic leukemia. The duration of remissions was somewhat shorter for children with acute lymphocytic leukemia than for adults with acute myelocytic leukemia. The frequency of remission, either partial or complete, was higher in children, however (36 per cent), than in adults (19 per cent), although the confidence limits for each figure overlap. The duration of acute leukemia in previously untreated patients did not influence response to therapy from the two antimetabolite regimens in this study. In patients who had had prior antimetabolite therapy, however, complete remissions were attained less often than in previously untreated patients. The toxic manifestations encountered during the administration of these antimetabolites are described. Seventeen deaths occurred during this study, of which 8 occurred in the first 10 days, presumably from leukemia and not drug toxicity. Five patients died with hypoplastic marrows ascribed to drug toxicity. The toxic manifestations were qualitatively and proportionately the same in patients who attained remission status, and in those patients who failed to remit, but who lived long enough to recognize the onset of remission if it were going to occur. No indication was obtained, therefore, that patients who attained remission were subjected to a greater toxic hazard, in order to achieve the therapeutic benefits observed, than those who did not remit. The median survival of patients who achieved remission was longer (p <.05) than for patients who did not remit. Since the survival time of remitters from relapse to death was almost identical with the survival time of nonremitters from onset of treatment to death, this difference can be accounted for by the time spent in remission and getting to remission. The median survival time from symptomatic onset for all children in this study was 12 months, and for adults, 7 months. The median in children is similar to that reported from other clinics. This is evidence that a comparative therapeutic trial in acute leukemia can be accomplished without recognizable compromise of patient welfare.

scholarly journals Association between thrombocyte and neutrophyl count with cutaneous manifestations in children with acute lymphocytic leukemia and acute myelocytic leukemia

2019 ◽  
Vol 7 (2) ◽  
pp. 551
Author(s):  
Eva Hariani ◽  
Sri Wahyuni Purnama ◽  
Remenda Siregar
Keyword(s):  
Acute Leukemia ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
P Value ◽  
Acute Myelocytic Leukemia ◽  
Cross Sectional ◽  
Hematopoietic Stem ◽  
Cutaneous Manifestations ◽  
Peripheral Tissues ◽  
Myelocytic Leukemia

Background: Acute leukemia is a hematopoietic stem cell malignant disease, with abnormal proliferation of leukemic and immature cells that suppress the production of normal blood cell and extensively invade peripheral tissues organs including skin. Homeostatic abnormalities that occur in leukemia e.g. thrombocytopenia and neutropenia. Various cutaneous manifestations can be observed in leukemia but the etiology is usually unknown, because many factors are responsible for this cutaneous manifestation. The aim of the present study was to determine association between thrombocyte and neutrophyl count with cutaneous manifestations in children with Acute Lymphocytic Leukemia (ALL) and Acute Myelocytic Leukemia (AML).Methods: This is an observational analytical cross-sectional study involving 51 children with acute leukemia (ALL and AML) were hospitalized in H. Adam Malik General Hospital Medan during April – September 2018. Interview, dermatology examination and recording thrombocyte and neutrophil count were performed to the subjects. Differences between thrombocyte and neutrophyl count with cutaneous manifestations were analyzed using Mann Whitney test. Association between thrombocyte and neutrophyl count with cutaneous manifestations were analyzed using Kolmogorov Smirnov test.Results: Children with Acute Leukemia in this study most of them were girls (51.0%), age between 0 - 5years old (39.2%). There were no significant differences between thrombocyte and neutrophyl count with cutaneous manifestations in children with acute leukemia (p value 0.692 and 0.814). There was no significant association between thrombocyte and neutrophyl count with cutaneous manifestations in children with acute leukemia (p value 0.490 and 0.803).Conclusions: There is no significant association between thrombocyte and neutrophyl count with cutaneous manifestations in children with acute leukemia.

scholarly journals A monoclonal antibody cross-reactive with human platelets, megakaryocytes, and common acute lymphocytic leukemia cells

Blood ◽  
1983 ◽  
Vol 61 (4) ◽  
pp. 759-764
Author(s):  
CT Deng ◽  
PI Terasaki ◽  
Y Iwaki ◽  
FM Hofman ◽  
P Koeffler ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Gel Electrophoresis ◽  
Acute Lymphocytic Leukemia ◽  
Blast Crisis ◽  
Human Platelets ◽  
Lymphocytic Leukemia ◽  
Leukemia Cells ◽  
Platelet Activity ◽  
Myelocytic Leukemia ◽  
Single Antigen

A cytotoxic monoclonal antibody, CALL1, produced against a human schwannoma tumor was found to react with human platelets, common acute lymphocytic cells (cALL), and lymphoblasts from lymphoid blast crisis of chronic myelocytic leukemia (CML). The hybridoma was repeatedly cloned, and the antibody was considered reactive to a single antigen by absorption tests demonstrating that platelets remove cALL activity and cALL cells absorb platelet activity from the antibody. In addition, chromatofocusing showed that the antibody against platelets and cALL had the same isoelectric point. The CALL1 antibody bound to megakaryocytes but inhibited neither myeloid (CFU-C) nor erythroid (BFU- E) colony formation from bone marrow stem cells. Immunoprecipitation and SDS-gel electrophoresis indicated that CALL1 reacts with a polypeptide of 26,000 daltons.

Sign in / Sign up

Export Citation Format

Share Document